p21-activated kinase 1 (PAK1) expression correlates with prognosis in solid tumors: A systematic review and meta-analysis

Fang Fang; Jian Pan; Yi-Ping Li; Gang Li; Li-Xiao Xu; Guang-Hao Su; Zhi-Heng Li; Xing Feng; Jian Wang

doi:10.18632/oncotarget.8320

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

p21-activated kinase 1 (PAK1) expression correlates with prognosis in solid tumors: A systematic review and meta-analysis

Fang Fang _, Jian Pan, Yi-Ping Li, Gang Li, Li-Xiao Xu, Guang-Hao Su, Zhi-Heng Li, Xing Feng and Jian Wang

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2016; 7:27422-27429. https://doi.org/10.18632/oncotarget.8320

Metrics: PDF 1932 views | HTML 2101 views | ?

Abstract

Fang Fang1, Jian Pan1, Yi-Ping Li1, Gang Li1, Li-Xiao Xu1, Guang-Hao Su1, Zhi-Heng Li1, Xing Feng1, Jian Wang1

1Institute of Pediatric Research, Children’s Hospital of Soochow University, Suzhou 215025, Jiangsu, China

Correspondence to:

Jian Wang, e-mail: [email protected]

Xing Feng, e-mail: [email protected]

Keywords: PAK1, solid tumor, prognosis, survival, meta-analysis

Received: November 25, 2015 Accepted: March 14, 2016 Published: March 24, 2016

ABSTRACT

p21 protein (Cdc42/Rac)-activated kinase 1 (PAK1) expression appears to be predictive of prognosis in various solid tumors, though the evidence is not yet conclusive. We therefore performed a meta-analysis to explore the relationship between PAK1 and prognosis in patients with solid tumors. Relevant publications were searched in several widely used databases, and 15 studies (3068 patients) were included in the meta-analysis. Pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated to evaluate the strength of the association between PAK1 and prognosis. Associations between PAK1 expression and prognosis were observed for overall survival (HR = 2.81, 95% CI = 1.07-7.39) and disease-specific survival (HR = 2.15, 95% CI = 1.47-3.16). No such association was detected for time to tumor progression (HR = 1.78, 95% CI = 0.99-3.21).Our meta-analysis thus indicates that PAK1 expression may be a predictive marker of overall survival and disease-specific survival in patients with solid tumors.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 8320

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Papers:

p21-activated kinase 1 (PAK1) expression correlates with prognosis in solid tumors: A systematic review and meta-analysis

Abstract